Certara (NASDAQ:CERT) Sees Large Volume Increase

Shares of Certara, Inc. (NASDAQ:CERT) saw strong trading volume on Wednesday . 263,246 shares were traded during mid-day trading, a decline of 58% from the previous session’s volume of 619,784 shares.The stock last traded at $11.92 and had previously closed at $11.80.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. UBS Group cut their price target on Certara from $20.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. JMP Securities reaffirmed a “market perform” rating on shares of Certara in a report on Wednesday, July 10th. KeyCorp lowered their price target on shares of Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Robert W. Baird reduced their price objective on Certara from $19.00 to $18.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Finally, Barclays decreased their target price on Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Friday, June 28th. Seven investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $17.79.

Certara Stock Performance

The stock’s 50-day simple moving average is $13.94 and its 200-day simple moving average is $15.88. The stock has a market cap of $1.84 billion, a price-to-earnings ratio of -29.38, a price-to-earnings-growth ratio of 5.71 and a beta of 1.49. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The company had revenue of $93.31 million for the quarter, compared to analyst estimates of $96.01 million. Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The company’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.10 EPS. Analysts forecast that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Pineridge Advisors LLC bought a new stake in Certara during the fourth quarter worth about $28,000. Global Retirement Partners LLC raised its position in shares of Certara by 5,306.3% in the 1st quarter. Global Retirement Partners LLC now owns 1,730 shares of the company’s stock valued at $31,000 after buying an additional 1,698 shares in the last quarter. Blue Trust Inc. bought a new stake in shares of Certara during the 2nd quarter worth approximately $26,000. Innealta Capital LLC acquired a new stake in shares of Certara during the 2nd quarter worth approximately $36,000. Finally, YHB Investment Advisors Inc. bought a new position in Certara in the first quarter valued at approximately $47,000. Institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.